Motley Fool
0
All posts from Motley Fool
Motley Fool in Motley Fool,

Why Mednax Tumbled 12% Today Despite Higher Sales

What happened

Despite reporting 9.2% year-over-year sales growth, a sharp decline in profitability sent shares in Mednax (NYSE: MD) lower Friday. Shares were down 11.9% at noon EDT.

So what

Mednax is a large provider of neonatal and anesthesia services to medical facilities. In the past, it has relied heavily on acquiring physician practices to fuel growth; however, in the second quarter, acquisitions failed to offset headwinds due to rising costs and a drop-off in organic admissions. 

IMAGE SOURCE: GETTY IMAGES.

Overall, Mednax's sales increased 9.2% to $842.9 million. Acquisitions accounted for 10.1% of revenue, however, and were offset by a 0.9% decline in revenue in its organic business. That dropoff was due to its patient mix tilting more toward government payers -- from which payments are lower -- and fewer admissions.

On the bottom line, Mednax's results were crimped by costs associated with its acquisitions, as well as wage growth for its physicians and other employees. The company's net income in the second quarter was $63.7 million, or $0.69 per share, down from $82.4 million, or $0.89 per diluted share, in Q2 2016.

Now what

The company's guidance for the third quarter isn't much better. Management forecasts that comparable sales will be flat to down 2% versus last year, and that EPS will be between $0.66 to $0.71. After adjusting for one-time expenses, EPS is expected to be between $0.83 to $0.88. For perspective, in Q3 2016, Mednax reported unadjusted and adjusted EPS of $1.04 and $1.09, respectively. 

Acquisitions will continue to support this company; however, until same-store revenue ticks higher and costs flatten out as a percentage of revenue, it's probably best to take a wait-and-see approach to Mednax stock. 

10 stocks we like better than MEDNAX
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and MEDNAX wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of July 6, 2017

 

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.